Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Hold” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $42.5556.

Several analysts have recently weighed in on AGIO shares. Royal Bank Of Canada lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. HC Wainwright decreased their target price on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Truist Financial upped their target price on Agios Pharmaceuticals from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Bank of America increased their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday.

Agios Pharmaceuticals Stock Down 2.8%

Shares of Agios Pharmaceuticals stock opened at $42.76 on Thursday. The stock’s fifty day moving average is $31.17 and its two-hundred day moving average is $29.67. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a market capitalization of $2.54 billion, a PE ratio of -5.90 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm’s revenue for the quarter was up 137.7% on a year-over-year basis. As a group, research analysts anticipate that Agios Pharmaceuticals will post -6.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its position in Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the period. MPM Bioimpact LLC purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $35,478,000. State Street Corp lifted its position in shares of Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares during the period. TCG Crossover Management LLC boosted its stake in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after purchasing an additional 733,038 shares in the last quarter. Finally, Capital International Investors bought a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $19,159,000.

Agios Pharmaceuticals News Roundup

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: The FDA granted Priority Review to Agios’ mitapivat sNDA in sickle cell disease, speeding up the path to a potential approval decision. U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
• Positive Sentiment: Bank of America raised its price target on AGIO to $46 and kept a buy rating, while Truist also lifted its target to $41, signaling improving Street sentiment. Benzinga report on analyst price target changes
• Positive Sentiment: Unusual call-option activity suggested traders were positioning for further upside ahead of the FDA catalyst and related momentum. Agios gains FDA priority review for Pyrukynd label expansion
• Neutral Sentiment: Some commentary noted that the recent rally may already be pricing in the FDA win, and that earnings estimate revisions do not clearly point to more near-term strength.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.